Cointime

Topigen Pharmaceuticals

company

About

TOPIGEN is a biotech company engaged in scientific research and development of novel therapeutic drugs.

  • 51 - 100

Highlights

Total Funding Amount
$28.60M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Series B
Last Funding Money Raised
$6M
Industries
Biotechnology,Developer Tools,Product Research,Therapeutics
Founded date
Jan 1, 2000
Number Of Employee
51 - 100
Operating Status
Active

Topigen Pharmaceuticals is a biotechnology company that is focused on the scientific research and development of therapeutic drugs. It develops treatments for respiratory disorders, including asthma and chronic obstructive pulmonary disease.

Topigen Pharmaceuticals offers TPI ASM8, a drug that is developed for the management of moderate to severe asthma; and TPI 1100, a drug that is developed for the chronic obstructive pulmonary disease.

Topigen Pharmaceuticals was acquired by Pharmaxis in January 2010.

Topigen Pharmaceuticals was founded in 2000 and is based in Montreal, Quebec.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$28.60M
Topigen Pharmaceuticals has raised a total of $28.60M in funding over 2 rounds. Their latest funding was raised on Oct 10, 2005 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 10, 2005 Series B $6M 2 — — Detail
Dec 1, 2004 Series Unknown $22.60M 2 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
Topigen Pharmaceuticals is funded by 2 investors. T2C2 Capital and Innovatech Grand Montreal are the most recent investors.
Investor Name Lead Investor Funding Round
T2C2 Capital — Series B
Innovatech Grand Montreal — Series B
Cointime
Content
Company